Biopharmaceutical company Radius Health has completed enrolment in a Phase III study of BA058-subcutaneous as a treatment for osteoporosis in postmenopausal women at high risk of fracture.

The company is developing BA058, a bone-building synthetic peptide analog, in both subcutaneous (BA058-SC) and transdermal patch (BA058-TD) formulations.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Radius Health chief medical officer Dr Louis Brenner said; "We are grateful for the efforts of our patients, investigators, and research collaborators to bring the pivotal study of BA058-SC to this key point, and we look forward to their continued contributions through the treatment and follow-up phases of the study."

"The double-blind trial’s primary endpoint is the efficacy of BA058-SC daily injection compared to placebo in preventing new vertebral fractures over 18 months of treatment."

The Phase III trial for BA058-SC reached its enrolment target of 2,400 subjects, and final subjects entering the study have been randomised.

The double-blind trial’s primary endpoint is the efficacy of BA058-SC daily injection compared to placebo in preventing new vertebral fractures over 18 months of treatment.

See Also:

Forteo, marketed by Eli Lilly, is an active comparator arm of the placebo-controlled study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Center for Clinical and Basic Research founder, Nordic Bioscience board chairman and radius advisor Dr Claus Christiansen said; "We are excited to have contributed to the achievement of BA058’s research milestones and we are optimistic about the potential for BA058 to provide a novel anabolic treatment option for postmenopausal osteoporosis patients."

In a Phase II study, BA058-SC was safe and well tolerated, demonstraing a considerable increase in bone mineral density at the lumbar spine and femoral neck following six months of therapy in women with osteoporosis.